This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Encompass Health (EHC) Opens Hospital, Boosts Texas Presence
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Texas, which reinforces the company's efforts to broaden presence in the state.
The Zacks Analyst Blog Highlights: Interactive Brokers, Etsy and Penumbra
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Interactive Brokers, Etsy and Penumbra
Top Stock Picks for Week of March 29, 2021
by Panel Of Zacks Experts
Top Picks for Investors Interested in the Shipping and Medical Space.
Has Penumbra (PEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PEN) Outperforming Other Medical Stocks This Year?
Penumbra (PEN) Launches INDIGO System Lightning 7 in US
by Zacks Equity Research
Penumbra's (PEN) INDIGO System Lightning 7 assists physicians in easing arterial thrombus removal with single-session results.
Buy These 5 Low-Beta Stocks & Combat the Choppy Market
by Nilanjan Banerjee
Low-beta stocks may be able to help sail through the choppy market conditions.
Penumbra, Silk Road Medical, EOG Resources, Diamondback Energy and ConocoPhillips highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Penumbra, Silk Road Medical, EOG Resources, Diamondback Energy and ConocoPhillips highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Silk Road Medical (SILK)
by Kevin Cook
Young innovator in stroke prevention has impressive sales growth but EPS just got slashed
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Leader in treating stroke with catheter-based technology has fully recovered from a product recall
The Zacks Analyst Blog Highlights: Deere & Co, The Mosaic Co, Penumbra, Denbury and Goldman Sachs
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Deere & Co, The Mosaic Co, Penumbra, Denbury and Goldman Sachs
6 Surging Top Large Caps With Room to Grow on Reopening Hopes
by Nalak Das
We have selected six large caps from cyclical sectors that have popped more than 25% year to date and still have strong upside left for 2021. These are: DE, MOS, PEN, GS, LB and DEN.
Zacks.com featured highlights include: Owens & Minor, Sturm Ruger & Company, Natus Medical, Penumbra and Toyota Motor
by Zacks Equity Research
Zacks.com featured highlights include: Owens & Minor, Sturm Ruger & Company, Natus Medical, Penumbra and Toyota Motor
Looking for a Growth Stock? 3 Reasons Why Penumbra (PEN) is a Solid Choice
by Zacks Equity Research
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 625.00% and 1.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bear of the Day: Penumbra (PEN)
by Kevin Cook
Revolutionary catheter-based treatment for stroke events encounters device problems and a recall
Penumbra (PEN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 146.15% and 20.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q3 Earnings on Oct 28: BSX, CERN & More
by Urmimala Biswas
In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 37.50% and 6.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Penumbra (PEN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Impinj, Penumbra, Microsoft, Apple and Amazon highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Impinj, Penumbra, Microsoft, Apple and Amazon highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Penumbra (PEN)
by Kevin Cook
Growth stalls for an innovator in blood clot removal and the deadly shadow of stroke with catheter-based aspiration technologies
Medical Products Stock Earnings on May 7: BDX, ABC & More
by Trina Mukherjee
Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.
Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.